Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

NCT ID: NCT00235391

Last Updated: 2011-06-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1683 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thalassemia Sickle Cell Disease Diamond Blackfan Anemia Myelofibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Deferasirox

Deferasirox was administered orally once a day, 30 minutes prior to breakfast. Dosage was based on participant's body weight. Starting dose was determined by the frequency of blood transfusions and recommended initial daily dose of deferasirox is 20 mg/kg body weight for patients receiving blood transfusion, 10 mg/kg for patients receiving less frequent transfusion/exchange transfusion and 30 mg/kg for patients receiving more frequent blood transfusions.

Group Type EXPERIMENTAL

Deferasirox

Intervention Type DRUG

125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deferasirox

125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients greater than or equal to 2 years of age
* Documented congenital disorder of red blood cells (e.g., β-thalassemia major, sickle cell anemia, diamond-blackfan anemia) requiring ongoing blood transfusions
* Cannot be adequately treated with a locally approved iron chelator due to one of the following reasons:

* Documented non-compliance, defined as having taken less than 50% of the prescribed chelation therapy doses in the 12 months prior to study entry
* Contraindications, unacceptable toxicities and/or documented poor response to locally approved iron chelators despite proper compliance
* History of at least 20 blood transfusions (equivalent to 100 mL/kg of packed red blood cells (PRBC\])
* Serum ferritin value greater than or equal to 1000 µg/L
* Ability to comply with all study-related procedures, medications, and evaluations

Exclusion Criteria

* Ongoing treatment with another iron chelator (Any other iron chelation therapy must be discontinued at least 24 hours prior to study entry.)
* Patients who meet the eligibility criteria for any other ongoing Novartis sponsored clinical study protocol with deferasirox and who have geographic access to these sites
* Patients unable to tolerate (or who have unacceptable toxicities to) prior treatment with deferasirox
* Serum creatinine above the upper limit of normal at screening.
* Patients with ALT ≥ 500 U/L at screening.
* Evidence of chelation-related cataracts or hearing loss within 4 weeks prior to baseline
* Pregnancy (as indicated by serum β-HCG pregnancy test at screening for all female patients with the potential to become pregnant) and patients who are breastfeeding
* Patients treated with systemic investigational drug within 4 weeks prior to or with topical investigational drug within 7 days prior to the baseline visit
Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Novartis Pharmaceuticals

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arkansas Children's Hospital, UAMS College of Medicine

Little Rock, Arkansas, United States

Site Status

Alta Bates Comprehensive Cancer Center

Berkeley, California, United States

Site Status

Children's Hospital of Orange County

Orange, California, United States

Site Status

Children's Hospital and Health Center of San Diego

San Diego, California, United States

Site Status

Stanford University

Stanford, California, United States

Site Status

Alfred I. Dupong Hospital for Children

Wilmington, Delaware, United States

Site Status

Osler Medical, Inc.

Melbourne, Florida, United States

Site Status

Hematalogy Oncology Associates

Pensacola, Florida, United States

Site Status

Tampa Children's Hospital at St. Joseph's Hospital

Tampa, Florida, United States

Site Status

James A. Haley Veterans Hospital

Tampa, Florida, United States

Site Status

Backus Children's Hospital, Memorial Health University Medical Center

Savannah, Georgia, United States

Site Status

Hematalogy Oncology Clinic

Baton Rouge, Louisiana, United States

Site Status

Borgess Hospital

Kalamazoo, Michigan, United States

Site Status

Children's Hospitals and Clinics of Minnesota

Minneapolis, Minnesota, United States

Site Status

University of Mississippi Medical Center

Jackson, Mississippi, United States

Site Status

Children's Mercy Hospital

Kansas City, Missouri, United States

Site Status

The Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Site Status

Schneider Children's Hospital

New Hyde Park, New York, United States

Site Status

PCTI

Columbus, Ohio, United States

Site Status

The Children's Medical Center of Dayton

Dayton, Ohio, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Children's Hospitals of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

Texas Children's Hospital

Houston, Texas, United States

Site Status

Children's Hospital of the Kings Daughters

Norfolk, Virginia, United States

Site Status

VCU Pediatric Hematology/Oncology

Richmond, Virginia, United States

Site Status

University of Washington Seattle Cancer Care Alliance

Seattle, Washington, United States

Site Status

Ziekenhuisnetwerk Antwerpen-AZ Middelheim

Antwerp, , Belgium

Site Status

Centre Hospitalier Notre Dame et Reine

Charleroi, , Belgium

Site Status

CHR de la Citadelle

Liège, , Belgium

Site Status

Centre Hospitalier Chretien-Clinique Saint-Joseph

Montegnée, , Belgium

Site Status

The Ottawa Hospital-General Campus

Ottawa, Ontario, Canada

Site Status

University of Alberta

Edmonton, , Canada

Site Status

CHUM-Hopital-Notre-Dame

Montreal, , Canada

Site Status

MUHC- Montreal Children's Hospital

Montreal, , Canada

Site Status

MUHC- Royal Victoria Hospital

Montreal, , Canada

Site Status

Hopital de l'Enfant-Jesus

Québec, , Canada

Site Status

The Hospital for Sick Children,

Toronto, , Canada

Site Status

Toronto General Hospital-Hemoglobinopathy

Toronto, , Canada

Site Status

Burrard Medical Building

Vancouver, , Canada

Site Status

Charite-Universitatsmedizin Berlin

Berlin, , Germany

Site Status

Universitatsklinikum Koln

Cologne, , Germany

Site Status

Universitaetsklinik Dusseldorf

Düsseldorf, , Germany

Site Status

Johann Wolfgang von Goethe Universitat

Frankfurt am Main, , Germany

Site Status

Georg-August-Universitat Gottingen

Göttingen, , Germany

Site Status

Universitatskrankenhaus Hamburg-Eppendorf

Hamburg, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Klinikum Stuttgart Bismarckstrasse 8

Stuttgart, , Germany

Site Status

Universitatsklinikum Ulm

Ulm, , Germany

Site Status

Agia Sofia Hospital of Athens

Athens, , Greece

Site Status

General Hospital of Athens

Athens, , Greece

Site Status

Ippokration Hospital of Athens

Athens, , Greece

Site Status

General Hospital of Athens

Corfu, , Greece

Site Status

General Hospital of Korinthos

Corinth, , Greece

Site Status

General Hospital of Heraklion Benizeleio-Pananeio

Heraklion, , Greece

Site Status

University Hospital of Ioannina

Ioannina, , Greece

Site Status

General Hospital of Kalamata

Kalamata, , Greece

Site Status

Agia Sofia Hospital of Athens

Karditsa, , Greece

Site Status

General Hospital of Karditsa

Karditsa, , Greece

Site Status

General Hospital of Larisa Tsakalof 1

Larissa, , Greece

Site Status

General Hospital of Mytilini Vostaneio

Mytilene, , Greece

Site Status

General State Hospital of Nikaia St. Panteleimon

Nikaia, , Greece

Site Status

University Hospital of Patras

Pátrai, , Greece

Site Status

General Hospital of Thessaloniki Agios Pavlos

Thessaloniki, , Greece

Site Status

General Hospital Thessalonikis Hippokratio

Thessaloniki, , Greece

Site Status

General Hospital of Volos

Volos, , Greece

Site Status

General Hospital of Xanthi

Xánthi, , Greece

Site Status

Presidio Ospedale Muscatello

Augusta, , Italy

Site Status

A.O. Ospedale Policlinico Consorziale di Bari

Bari, , Italy

Site Status

Presidio Ospedaliero Antonio Perrino

Brindisi, , Italy

Site Status

Ospedale Regionale Microcitemie

Cagliari, , Italy

Site Status

Ospedale Di Venere

Carbonara di Bari, , Italy

Site Status

Azienda Ospedali Vittorio Emanuele, Ferrarotto e San Bambino

Catania, , Italy

Site Status

Presidio Ospedaliero S. Bambino

Catania, , Italy

Site Status

PresidioOspedaliero S. Luigi Curro

Catania, , Italy

Site Status

Azienda Ospedaliera Pugliese Cicaccio

Catanzaro, , Italy

Site Status

Ospedale Civile dell'Annunziata

Cosenza, , Italy

Site Status

Ospedale San Giuseppe

Empoli, , Italy

Site Status

Azienda Ospedaliera Universitaria di Ferrara

Ferrara, , Italy

Site Status

Azienda Ospedaliera A. Meyer

Florence, , Italy

Site Status

E.O. Ospedali Galliera

Genova, , Italy

Site Status

Ospedale Regionale Microcitemie

Itala, , Italy

Site Status

Ospedale Madonna delle Grazie

Matera, , Italy

Site Status

Az. Ospedaliera Universitaria Policlinico G. Martino

Messina, , Italy

Site Status

Fondazione Ospedale

Milan, , Italy

Site Status

Azienda Ospedaliero-Universitaria di Modena

Modena, , Italy

Site Status

AORN A. Cardarelli

Napoli, , Italy

Site Status

Azienda Ospedaliera Universitaria Federico II

Napoli, , Italy

Site Status

Azienda Ospedaliera V. Cervello

Palermo, , Italy

Site Status

Azienda Ospedaliera Villa Sofia-CTO

Palermo, , Italy

Site Status

Presidio Ospedaliero Giovanni di Cristina

Palermo, , Italy

Site Status

IRCCS Policlinico San Matteo

Pavia, , Italy

Site Status

Azienda Ospedaliera San Salvatore

Pesaro, , Italy

Site Status

Azienda Ospedaliero Universitaria Pisana

Pisa, , Italy

Site Status

Azienda Ospedaliera Civile- Maria Paterno

Ragusa, , Italy

Site Status

Azienda Ospedaliera Bianchi-Melacrino-Morelli

Reggio Calabria, , Italy

Site Status

Ospedale S. Eugenio

Roma, , Italy

Site Status

Ospedale nostra Signora di Bonaria

San Gavino Monreale- CA, , Italy

Site Status

Presidio Ospedaliero di Sassari-Ospedale SS

Sassari, , Italy

Site Status

Azienda Ospedaliera Ospedali Civili Riuniti di Sciacca

Sciacca, , Italy

Site Status

Ospedale Umberto I

Talassemie, , Italy

Site Status

Presidio Ospedaliero Centrale

Taranto, , Italy

Site Status

Ospedale Infantile Regina Margherita

Torino, , Italy

Site Status

AMC

Amsterdam, , Netherlands

Site Status

Catharina-ziekenhuis

Eindhoven, , Netherlands

Site Status

Erasmus MC

Rotterdam, , Netherlands

Site Status

Erasmus Medisch Centrum, locatie Sophia

Rotterdam, , Netherlands

Site Status

Haga Ziekenhuis

The Hague, , Netherlands

Site Status

Hospital de Torrecardenas

Almería, , Spain

Site Status

Hospital Infanta Cristina

Badajoz, , Spain

Site Status

Hospital Cruces

Barakaldo, , Spain

Site Status

Hospital Puerta del Mar

Cadiz, , Spain

Site Status

Hospital De Gran Canaria

Canara, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Althaia : Xarxa Assistencial de Manresa

Manresa, , Spain

Site Status

Hospital Universitario Marques de Valdecilla

Santander, , Spain

Site Status

Hospital Virgen de la Salud

Toledo, , Spain

Site Status

Hospital Universitario La Fe

Valencia, , Spain

Site Status

Hospital Xeral de Vigo

Vigo, , Spain

Site Status

Kaohsiung Medical University Hospital

Kaohsiung City, , Taiwan

Site Status

Mackay Memorial Hospital

Taipei, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Chang Gung Children's Hospital

Taoyuan District, , Taiwan

Site Status

Tao-yuan General Hospital

Tau-Yuan County, , Taiwan

Site Status

Phramongkutklao Hospital

Bangkok, , Thailand

Site Status

Ramathibodi Hospital

Bangkok, , Thailand

Site Status

Songklanagarind Hospital

Bangkok, , Thailand

Site Status

Srinagarind Hospital

Khon Kaen, , Thailand

Site Status

Cukurova Universitesi

Adana, , Turkey (Türkiye)

Site Status

Hacettepe Universitesi

Ankara, , Turkey (Türkiye)

Site Status

Akdeniz Universitesi

Antalya, , Turkey (Türkiye)

Site Status

Gaziantep Universitesi

Gaziantep, , Turkey (Türkiye)

Site Status

Suleyman Demirel

Isparta, , Turkey (Türkiye)

Site Status

Istanbul Universitesi

Istanbul, , Turkey (Türkiye)

Site Status

Ege Universitesi Tip Fakultesi

Izmir, , Turkey (Türkiye)

Site Status

Erciyes Universitesi

Kayseri, , Turkey (Türkiye)

Site Status

Evelina Hospital St. Thomas' Hospital

London, , United Kingdom

Site Status

North Middlesex University Hospital

London, , United Kingdom

Site Status

The Royal Hospital London

London, , United Kingdom

Site Status

Whittington Hospital

London, , United Kingdom

Site Status

St. George's Hospital

Tooting, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Canada Germany Greece Italy Netherlands Spain Taiwan Thailand Turkey (Türkiye) United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

http://www.novartisclinicaltrials.com/

Visit NovartisClinicalTrials.com: Pre-qualify for a trial, and view a list of trials and participating study centers.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CICL670A2203

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.